Table 2.
Proinflammatory cytokines, lymphocytes, and regulatory T (Treg) cells in the study subjects
| Nondiabetic rats (n=10) | Diabetic rats (n=10) | Diabetic rats treated with MCA (n=10) | Diabetic rats treated with MCA NPs (n=10) | P1a | P2b | P3c | P4d | |
|---|---|---|---|---|---|---|---|---|
| IL1β, pg/mL | 139.53±31.4 | 912±150 | 543±94.5 | 421±90.6 | <0.001 | 0.01 | <0.001 | ns |
| IL6, pg/mL | 50.23±24.3 | 920±124 | 448±110 | 302.5±65 | <0.001 | 0.04 | 0.01 | 0.04 |
| TNFα, pg/mL | 56.6±20.5 | 883.43±90.5 | 509.2±88.12 | 261.23±59.8 | <0.001 | 0.001 | 0.03 | 0.01 |
| Lymphocytes (%) | 56.32±2.8 | 49.21±7.74 | 53.77±7.39 | 51.87±8.33 | 0.01 | ns | ns | ns |
| CD4+ T cells (%) | 39.1±6.50 | 26.65±6.48 | 35.01±1.22 | 36.54±2.81 | 0.012 | 0.03 | 0.01 | ns |
| CD4+CD25+Foxp3+ Treg cells (%) | 1.41±0.29 | 1.06±0.07 | 1.89±0.37 | 2.04±0.34 | 0.04 | 0.0002 | 0.02 | 0.001 |
Notes: Data presented as mean ± SD. Mann–Whitney test P≤0.05 significant.
a
Comparison between diabetic rats and nondiabetic controls;\
b
comparison between rats treated with MCA and diabetic rats;
c
comparison between rats treated with MCA NPs and diabetic rats;
d
comparison between rats treated with MCA NPs and rats treated with MCA.
Abbreviations: MCA, metoclopramide; ns, not significant; NPs, nanoparticles.